CL2019000042A1 - Composiciones farmacéuticas - Google Patents

Composiciones farmacéuticas

Info

Publication number
CL2019000042A1
CL2019000042A1 CL2019000042A CL2019000042A CL2019000042A1 CL 2019000042 A1 CL2019000042 A1 CL 2019000042A1 CL 2019000042 A CL2019000042 A CL 2019000042A CL 2019000042 A CL2019000042 A CL 2019000042A CL 2019000042 A1 CL2019000042 A1 CL 2019000042A1
Authority
CL
Chile
Prior art keywords
pharmaceutical compositions
compositions
solid pharmaceutical
contain
methods
Prior art date
Application number
CL2019000042A
Other languages
English (en)
Inventor
Corswant Christian Von
Romain Bordes
Jonasson Simon Peter Michael Hjelm
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2019000042A1 publication Critical patent/CL2019000042A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE SOLICITUD SE REFIERE A COMPOSICIONES FARMACÉUTICAS SÓLIDAS Y FORMAS FARMACÉUTICAS SÓLIDAS QUE LAS CONTIENEN QUE COMPRENDEN ACEITES COMO SU PRINCIPIO ACTIVO FARMACÉUTICO. SE DESCRIBEN MÉTODOS PARA PREPARAR LAS COMPOSICIONES Y SUS USOS.
CL2019000042A 2016-07-08 2019-01-07 Composiciones farmacéuticas CL2019000042A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1611920.8A GB201611920D0 (en) 2016-07-08 2016-07-08 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CL2019000042A1 true CL2019000042A1 (es) 2019-04-12

Family

ID=56890842

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000042A CL2019000042A1 (es) 2016-07-08 2019-01-07 Composiciones farmacéuticas

Country Status (20)

Country Link
US (1) US20200254046A1 (es)
EP (1) EP3481377A1 (es)
JP (1) JP2019520393A (es)
KR (1) KR20190026816A (es)
CN (1) CN109414409A (es)
AU (1) AU2017298873B2 (es)
BR (1) BR112019000240A2 (es)
CA (1) CA3029331A1 (es)
CL (1) CL2019000042A1 (es)
CO (1) CO2019000083A2 (es)
CR (1) CR20190007A (es)
DO (1) DOP2019000002A (es)
EA (1) EA201990162A1 (es)
GB (1) GB201611920D0 (es)
IL (1) IL263999A (es)
MX (1) MX2019000255A (es)
PE (1) PE20190321A1 (es)
PH (1) PH12019500024A1 (es)
SG (1) SG11201811223YA (es)
WO (1) WO2018015175A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022071461A1 (es) * 2020-10-02 2022-04-07
JPWO2022071463A1 (es) * 2020-10-02 2022-04-07

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003238240A1 (en) * 2002-06-17 2003-12-31 Resolvyx Pharmaceuticals ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE
WO2008145183A1 (en) * 2007-05-30 2008-12-04 Nestec S.A. Oil-in-water emulsion and its use for the delayed release of active elements
GB2465988A (en) * 2008-12-03 2010-06-09 Omegatri As Powder or tablet containing unsaturated fatty acid and water insoluble carbohydrate
NZ595204A (en) * 2009-03-09 2014-11-28 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
CN102512664B (zh) * 2010-12-31 2015-04-01 舒泰神（北京）生物制药股份有限公司 一种神经生长因子组合物
RU2664429C2 (ru) 2012-01-06 2018-08-17 Омтера Фармасьютикалс, Инк. Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA

Also Published As

Publication number Publication date
EA201990162A1 (ru) 2019-06-28
JP2019520393A (ja) 2019-07-18
WO2018015175A9 (en) 2018-03-29
SG11201811223YA (en) 2019-01-30
AU2017298873A1 (en) 2019-02-14
PE20190321A1 (es) 2019-03-04
DOP2019000002A (es) 2019-03-31
WO2018015175A1 (en) 2018-01-25
IL263999A (en) 2019-01-31
MX2019000255A (es) 2019-05-27
PH12019500024A1 (en) 2019-11-04
AU2017298873B2 (en) 2020-04-30
CA3029331A1 (en) 2018-01-25
CN109414409A (zh) 2019-03-01
CR20190007A (es) 2019-03-05
CO2019000083A2 (es) 2019-01-18
KR20190026816A (ko) 2019-03-13
GB201611920D0 (en) 2016-08-24
BR112019000240A2 (pt) 2019-04-16
EP3481377A1 (en) 2019-05-15
US20200254046A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
CL2017003389A1 (es) Composiciones de pienso para animales y usos de las mismas.
CL2017003404A1 (es) Compuestos antibacterianos
GT201600185A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
CL2016003056A1 (es) Dinucleótidos ciclicos moduladores de sting; composición y combinación farmacéutica que los comprende y uso de los mismos para el tratamiento de enfermedades tales como inflamación, enfermedades alérgicas y autoinmunes, enfermedades infecciosas y cancer.
CL2015002239A1 (es) Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos
CO2018000648A2 (es) Compuestos de piridina sustituidos, intermediarios para su preparación y composiciones que los comprenden
SV2017005419A (es) Triazolopirazinonas como inhibidores de pde1
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
BR112017000039A2 (pt) composições agrícolas e aplicações que utilizam óleos essenciais
CL2016002300A1 (es) Combinaciones de principios activos insecticidas y nematocidas
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
NI201300080A (es) Formas sólidas de 3 - ( 5 - amino - 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il ) - piperidin - 2, 6 - diona, y sus composiciones farmacéuticas y usos
UY36499A (es) Uso de picolinamidas como fungicidas
CL2019001736A1 (es) Polimorfos.
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
AR095542A1 (es) Compuestos heterocíclicos y sus usos
CL2019001737A1 (es) Polimorfos.
CO2018001756A2 (es) Concentrados en suspensión aceitosa con baja separación gravimétrica y baja viscosidad
BR112016025659A2 (pt) compostos, seus usos, e composições farmacêuticas para induzir condrogênese
CL2017002170A1 (es) Desacetoxitubulisina h y análogos de esta.
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
CO2019006424A2 (es) Proteínas de unión a antígenos anti-gitr y métodos de uso de las mismas
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
UY37432A (es) Moléculas que tienen actividad pesticida, compuestos intermedios, composiciones y procesos relacionados
BR112016027379A2 (pt) formulações tópicas e seus usos